Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects

NCT01624714 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Alemtuzumab
DRUG: Alemtuzumab immunotherapy

Sponsor

Samuel Forrester Hunter, MD, PhD